Top of the Street: Smith+ Nephew, Chr Hansen, Accor

Novozymes A/S

03/11/2023 14:09

A round-up of notable broker activity this morning from Europe's
top-ranked* analysts:
    
    ** Barclays cuts Accor  ACCP.PA  to "equal weight" from
"overweight", saying Europe's biggest hotel group is at risk of
becoming a "value trap" due to its greater exposure to Middle
East compared to peers
    ** J.P.Morgan upgrades British medical products maker Smith+
Nephew  SN.L  to "overweight" from "neutral", saying that the
downgrade cycle that started in 2018 seems to be coming to an
end
    ** Barclays ups Danish consumer chemical groups Novozymes
 NZYMb.CO  and Chr Hansen  CHRH.CO  to "overweight" from "equal
weight", citing increased confidence on long-term growth
prospects for their future combined business

(*Analyst rankings from Thomson Reuters StarMine. The scale is
from 1-star to 5-star with 5 being the best. Analysts are ranked
on earnings accuracy as well as relative performance of
recommendations over trailing 12-month & 24-month periods.)


 (Reporting by Tristan Veyet and Diana Mandiá)
 ((Tristan.chabba@thomsonreuters.com))